Phoenix Asia Holdings terminates deal to acquire ACEA Pharma

• Phoenix Asia Holdings terminated its planned acquisition of ACEA Pharma on November 3, 2026, following a missed November 2 closing deadline.
• Under the May 4, 2026, agreement, ACEA Therapeutics would have received 100,000,000 newly issued ordinary shares for all target equity.
• The transaction will not proceed. No shares were issued, no target equity was transferred and no acquisition consideration was paid.
• The agreement carries no termination fee; each party generally bears its own costs and expenses.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phoenix Asia Holdings Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-050718), on November 09, 2026, and is solely responsible for the information contained therein.